Xenon PharmaceuticalsXENE
Market Cap: 3.32B
About: Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Employees: 259
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
441% more call options, than puts
Call options by funds: $25.6M | Put options by funds: $4.73M
67% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 21
22% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 65
7% more funds holding
Funds holding: 202 [Q4 2023] → 216 (+14) [Q1 2024]
0.11% less ownership
Funds ownership: 97.44% [Q4 2023] → 97.34% (-0.11%) [Q1 2024]
5% less capital invested
Capital invested by funds: $3.32B [Q4 2023] → $3.16B (-$155M) [Q1 2024]
29% less funds holding in top 10
Funds holding in top 10: 14 [Q4 2023] → 10 (-4) [Q1 2024]
Research analyst outlook
9 Wall Street Analysts provided 1 year price forecasts over the past 6 months
9 analyst ratings
RBC Capital Brian Abrahams | 25%upside $55 | Outperform Reiterated | 18 Jun 2024 |
Needham Serge Belanger | 41%upside $62 | Buy Maintained | 10 May 2024 |
Citigroup David Hoang | 36%upside $60 | Buy Maintained | 10 May 2024 |
Wedbush Laura Chico | 14%upside $50 | Outperform Maintained | 10 May 2024 |
Needham Serge Belanger | 41%upside $62 | Buy Reiterated | 12 Apr 2024 |